Last reviewed · How we verify
QazCovid-in®-vaccine against COVID-19 — Competitive Intelligence Brief
phase 3
Infectious Disease
Biologic
Live · refreshed every 30 min
Target snapshot
QazCovid-in®-vaccine against COVID-19 (QazCovid-in®-vaccine against COVID-19) — Research Institute for Biological Safety Problems. QazCovid-in stimulates an immune response to provide protection against COVID-19.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| QazCovid-in®-vaccine against COVID-19 TARGET | QazCovid-in®-vaccine against COVID-19 | Research Institute for Biological Safety Problems | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- QazCovid-in®-vaccine against COVID-19 CI watch — RSS
- QazCovid-in®-vaccine against COVID-19 CI watch — Atom
- QazCovid-in®-vaccine against COVID-19 CI watch — JSON
- QazCovid-in®-vaccine against COVID-19 alone — RSS
Cite this brief
Drug Landscape (2026). QazCovid-in®-vaccine against COVID-19 — Competitive Intelligence Brief. https://druglandscape.com/ci/qazcovid-in-vaccine-against-covid-19. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab